Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company’s web site at www.oncothyreon.com.
- 18 years ago
QualityStocks
Oncothyreon, Inc. (NASDAQ: ONTY)
Tags Rodman & Renshaw
Related Post
-
Wild Gold Discovery Drill Holes with Gold Over 200 Meters Intercepts at Lafleur Minerals (CSE: LFLR) (OTCQB: LFLRF) Swanson Gold Deposit Point Towards a District-Scale Gold Discovery
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)and may include paid advertising.…
-
HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions
Cardiovascular disease remains the leading cause of death in the United States. One of the…
-
Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Positions for Next Phase of Commercial Space Infrastructure Expansion
Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.…